Catheter Blood Articles & Analysis
9 news found
US-based MedSource Labs and Sydney’s Medilogic enter into an exclusive, strategic partnership in the peripheral safety IV market with the announcement of Logiflow Exactus and Logiflow Exactus Shield with Blood Control IV Catheters with active blood control check valve technology in ...
At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...
Occlusion or clogging of the ventricular catheter by blood, debris, or tissue is the primary cause of shunt failure. ...
MedSource Labs Moves the Needle in the Peripheral Safety IV Market With the announcement of ClearSafe Comfort® and TrueSafe Comfort® Blood Control IV Catheters with groundbreaking active check valve ...
” More specifically, the testing range of T,C&A Lab encompasses the following: l Repair materials for the skeletal-muscle system such as bones, teeth, joints, and tendons l Soft tissue materials such as skin, esophagus, respiratory tract, bladder and other l Cardiovascular system materials such as artificial heart valves, blood vessels, and cardiovascular ...
During AF ablation, a specialized cardiologist known as an electrophysiologist inserts catheters through the blood vessels into the heart to burn or freeze that tissue that is causing abnormal electrical signals in the upper chamber, or atrium. ...
The 2021 class of Leonhardt’s Launchpads Accelerator graduates include: MyoStim ED with ErectiStimTM: MyoStim ED is the first intervention for erectile dysfunction (ED) designed to address all major causes of ED: impaired blood flow, damaged blood vessels, nerve damage, and muscle deterioration. ...
The Hemolung is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected. ...
Not surprising as the Vascular Access discipline can easily document its financial value by demonstrating up to millions in cost savings by reducing the number of central line-associated blood stream infections (CLABSIs) and/or complications and waste associated with peripheral intravenous catheters (PIVs). ...